Results indicate the relationship of the drug with terms associated to protein serine/threonine kinases and protein kinase B. In chronic myeloid leukemia studies, altered expression levels of key signaling molecules in the EGFR/MAPK pathway were observed in PD153035-treated mouse groups.62 This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.